Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

IMCD PEER ANALYSIS

IMCD NV — metric-by-metric comparison with peers and the industry median

IMCDIMCD NV

🇳🇱 Netherlands · AS · Basic Materials · Specialty Chemicals

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Specialty Chemicals

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
IMCDIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
IMCD-25.8%PRM+122.1%BCPC+4.1%SXT+20.3%DNL+48.8%CBT+12.1%
Year-to-Date (YTD)
IMCD+9.9%PRM+23.2%BCPC+10.1%SXT+33.5%DNL+23.9%CBT+31.8%
1-Year
Split-adjusted
IMCD-25.8%AKZA+4.3%DSFIR-2.0%
Year-to-Date (YTD)
IMCD+9.9%AKZA+5.8%DSFIR+28.4%

Key Metric Comparison

P/E

Lower is better
IMCD22.68PRM—BCPC34.47SXT36.84DNL—CBT15.98Median 27.62

ROE

Higher is better
IMCD10.2%PRM-15.7%BCPC12.7%SXT12.5%DNL3.8%CBT19.0%Median 4.4%

Net Margin

Higher is better
IMCD4.5%PRM-26.9%BCPC15.0%SXT8.7%DNL4.5%CBT8.0%Median 3.5%

Revenue Growth

Higher is better
IMCD1.2%PRM23.0%BCPC9.6%SXT5.8%DNL-16.6%CBT-8.5%Median 1.2%

P/E

Lower is better
IMCD22.68AKZA16.76DSFIR—Median 27.62

ROE

Higher is better
IMCD10.2%AKZA13.1%DSFIR-4.8%Median 4.4%

Net Margin

Higher is better
IMCD4.5%AKZA6.3%DSFIR-8.0%Median 3.5%

Revenue Growth

Higher is better
IMCD1.2%AKZA-7.0%DSFIR-2.7%Median 1.2%

All Metrics

Valuation
MetricIMCDPRMBCPCSXTDNLCBTInd. Median
P/E22.68—34.4736.84—15.98●27.62
P/B2.424.654.244.361.75●2.871.81
EV/EBITDA12.28—20.5521.4312.797.36●12.43
P/S1.03●7.935.153.211.901.261.70
Financial Health
MetricIMCDPRMBCPCSXTDNLCBTInd. Median
Current Ratio1.733.092.555.01●1.271.451.87
Debt/Equity83.4%113.4%14.4%●63.0%39.7%82.8%63.0%
NetDebt/EBITDA2.81-9.65●0.412.592.151.392.15
Profitability
MetricIMCDPRMBCPCSXTDNLCBTInd. Median
Net Margin4.5%-26.9%15.0%●8.7%4.5%8.0%3.5%
ROE10.2%-15.7%12.7%12.5%3.8%19.0%●4.4%
ROA4.6%-6.8%9.5%●6.6%2.2%7.4%2.0%
EBITDA Margin10.9%-18.7%25.6%●17.0%17.8%21.1%14.7%
Growth + Dividend
MetricIMCDPRMBCPCSXTDNLCBTInd. Median
Rev. Growth1.2%23.0%●9.6%5.8%-16.6%-8.5%1.2%
NI Growth-21.8%—15.8%●12.5%—-34.2%-4.8%
Div. Yield2.2%—0.6%1.3%3.6%●2.1%1.5%
Payout58.4%—19.5%48.3%126.7%34.0%9.1%
Valuation
MetricIMCDAKZADSFIRInd. Median
P/E22.6816.76●—27.62
P/B2.422.131.21●1.81
EV/EBITDA12.288.48●11.4012.43
P/S1.03●1.051.801.70
Financial Health
MetricIMCDAKZADSFIRInd. Median
Current Ratio1.73●1.721.591.87
Debt/Equity83.4%125.2%28.9%●63.0%
NetDebt/EBITDA2.811.941.51●2.15
Profitability
MetricIMCDAKZADSFIRInd. Median
Net Margin4.5%6.3%●-8.0%3.5%
ROE10.2%13.1%●-4.8%4.4%
ROA4.6%●4.1%-3.1%2.0%
EBITDA Margin10.9%16.0%18.2%●14.7%
Growth + Dividend
MetricIMCDAKZADSFIRInd. Median
Rev. Growth1.2%●-7.0%-2.7%1.2%
NI Growth-21.8%32.7%●—-4.8%
Div. Yield2.2%3.3%●3.0%1.5%
Payout58.4%56.0%-73.4%9.1%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on IMCD

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 3, 26. This content is for informational purposes only and is not investment advice.